Stability of T cell compartment during combined decitabine and ipilimumab treatment. (A) Donor chimerism across T/NK cell subsets (left) and longitudinal chimerism of CD4⁺, CD8⁺ and NK cells throughout treatment (right) for 8 posttransplant patients (arm A). Statistical testing using Wilcoxon rank-sum test. Shaded areas indicate 95% confidence interval. (B) Changes in TCR repertoire in transplant-naïve and posttransplant samples after decitabine (left) and ipilimumab treatment (right). Break-down by responders (Rs) and NRs shown in inset. Statistical testing using Fisher exact test and FDR correction for individual T-cell clones and Wilcoxon rank-sum test between responders and NRs (FDR < 0.05). (C) Ratio of CD8⁺ T cell to myeloid cell infiltration in bone marrow core biopsies estimated using quanTIseq from available bulk RNA-seq data of patients across both study arms. (D) Percentage of myeloid cells in screening bone marrow samples of NRs (n = 10) and responders (n = 8) using scRNA-seq data (left). T/NK cell to myeloid ratio for the same patients detailed throughout treatment (right). (E) Differential expression analysis of screening bone marrow plasma profiles between responders (n = 13) and NRs (n = 25) across both study arms. Statistical testing using Wilcoxon rank-sum test and FDR correction for multiple hypothesis testing (FDR < 0.05). (F) Principal component analysis of bone marrow plasma profiles from all available samples (n = 185) colored by clinical response (top) and study arm (bottom). (G) Expression of proteins associated with clinical response throughout treatment in responders and NRs. (H) Decrease in the number of cell-cell interactions detected using CellPhoneDB from scRNA-seq data across different cell subsets following decitabine and ipilimumab in responders (n = 8) compared with NRs (n = 10) and healthy donors (n = 8).